


**Amendments to the Claims:**

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.

**Listing of the Claims:**

1-16. (Cancelled).

17. (Previously presented) A compound of formula (I),



the *N*-oxide forms, the addition salts and the stereo-chemically isomeric forms thereof, wherein

*n* is 0, 1 or 2;

X is N or CR<sup>7</sup>, wherein R<sup>7</sup> is hydrogen or taken together with R<sup>1</sup> may form a bivalent radical of formula -CH=CH-CH=CH-;

R<sup>1</sup> is C<sub>1-6</sub>alkyl or thiophenyl;

R<sup>2</sup> is hydrogen, hydroxy, C<sub>1-6</sub>alkyl, C<sub>3-6</sub>alkynyl or taken together with R<sup>3</sup> may form =O; except that when X is N, R<sup>2</sup> together with R<sup>3</sup> cannot form =O;

R<sup>3</sup> is a radical selected from



wherein

*s* is 0, 1, 2 or 3;

R<sup>8</sup>, R<sup>10</sup> and R<sup>11</sup> are each independently selected from -CHO, C<sub>1-6</sub>alkyl, hydroxyC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkylcarbonyl, amino, C<sub>1-6</sub>alkylamino,

di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxycarbonyl, C<sub>1-6</sub>alkylcarbonylaminoC<sub>1-6</sub>alkyl,  
 piperidiny(C<sub>1-6</sub>alkylaminocarbonyl, piperidiny, piperidiny(C<sub>1-6</sub>alkyl,  
 piperidiny(C<sub>1-6</sub>alkylaminocarbonyl, C<sub>1-6</sub>alkyloxy, thiophenylC<sub>1-6</sub>alkyl,  
 pyrroly(C<sub>1-6</sub>alkyl, arylC<sub>1-6</sub>alkylpiperidiny, arylcarbonylC<sub>1-6</sub>alkyl,  
 arylcarbonylpiperidiny(C<sub>1-6</sub>alkyl, haloindozolylpiperidiny(C<sub>1-6</sub>alkyl,  
 arylC<sub>1-6</sub>alkyl(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl, and

R<sup>9</sup> is hydrogen or C<sub>1-6</sub>alkyl;










or R<sup>3</sup> is a group of formula




wherein

t is 0, 1, 2 or 3;

-Z is a heterocyclic ring system selected from



wherein R<sup>12</sup> is hydrogen, halo, C<sub>1-6</sub>alkyl, aminocarbonyl, amino, hydroxy, aryl,




C<sub>1-6</sub>alkylaminoC<sub>1-6</sub>alkyloxy, C<sub>1-6</sub>alkyloxyC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxyC<sub>1-6</sub>alkylamino, arylC<sub>1-6</sub>alkyl, di(phenylC<sub>2-6</sub>alkenyl), piperidinyl, piperidinylC<sub>1-6</sub>alkyl, C<sub>3-10</sub>cycloalkyl, C<sub>3-10</sub>cycloalkylC<sub>1-6</sub>alkyl, aryloxy(hydroxy)C<sub>1-6</sub>alkyl, haloindazolyl, arylC<sub>1-6</sub>alkyl, arylC<sub>2-6</sub>alkenyl, arylC<sub>1-6</sub>alkylamino, morpholino, C<sub>1-6</sub>alkylimidazolyl, pyridinylC<sub>1-6</sub>alkylamino; and

R<sup>13</sup> is hydrogen, piperidinyl or aryl;

R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are each independently selected from hydrogen, halo, trihalomethyl, trihalomethoxy, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, amino, aminoC<sub>1-6</sub>alkyl, di(C<sub>1-6</sub>alkyl)amino, di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyloxy or C<sub>1-6</sub>alkyloxycarbonyl, or C<sub>1-6</sub>alkyl substituted with 1, 2 or 3 substituents independently selected from hydroxy, C<sub>1-6</sub>alkyloxy, or aminoC<sub>1-6</sub>alkyloxy; or

when R<sup>5</sup> and R<sup>6</sup> are on adjacent positions they may taken together form a bivalent radical of formula



wherein R<sup>14</sup> is C<sub>1-6</sub>alkyl;


and aryl is phenyl, phenyl substituted with halo, C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkyloxy.

18. (Currently Amended) A compound as claimed in claim 17 wherein

R<sup>1</sup> is C<sub>1-6</sub>alkyl; R<sup>3</sup> is a radical selected from the group consisting of (a-1), (a-2), (a-3) or (a-5), and or is a group of formula (b-1) wherein -Z is a heterocyclic ring system selected from (c-1), (c-6), (c-8), (c-9), or (c-11); s is 0, 1 or 2; R<sup>8</sup> and R<sup>10</sup> are each independently selected from

-CHO, C<sub>1-6</sub>alkyl, hydroxyC<sub>1-6</sub>alkyl, di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl,


C<sub>1-6</sub>alkylcarbonylaminoC<sub>1-6</sub>alkyl, piperidinylC<sub>1-6</sub>alkyl,  
piperidinylC<sub>1-6</sub>alkylaminocarbonyl, C<sub>1-6</sub>alkyloxy, thiophenylC<sub>1-6</sub>alkyl,  
pyrrolylC<sub>1-6</sub>alkyl, arylC<sub>1-6</sub>alkylpiperidinyl, arylcarbonylC<sub>1-6</sub>alkyl,  
arylcarbonylpiperidinylC<sub>1-6</sub>alkyl, haloindozolylpiperidinylC<sub>1-6</sub>alkyl, or  
arylC<sub>1-6</sub>alkyl(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl; t is 0 or 2; ~~Z is a heterocyclic ring system  
selected from (c-1), (c-2), (c-4), (c-6), (c-8), (c-9), or (c-11);~~ R<sup>12</sup> is hydrogen,




C<sub>1-6</sub>alkyl, aminocarbonyl, C<sub>1-6</sub>alkyloxyC<sub>1-6</sub>alkylamino,  
di(phenylC<sub>2-6</sub>alkenyl), piperidinylC<sub>1-6</sub>alkyl, C<sub>3-10</sub>cycloalkyl,  
C<sub>3-10</sub>cycloalkylC<sub>1-6</sub>alkyl, haloindazolyl, or arylC<sub>2-6</sub>alkenyl; R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are each  
independently selected from hydrogen, halo, trihalomethyl, trihalomethoxy,  
C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, di(C<sub>1-6</sub>alkyl)amino, di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyloxy or  
C<sub>1-6</sub>alkyloxycarbonyl; and when R<sup>5</sup> and R<sup>6</sup> are on adjacent positions they may taken  
together form a bivalent radical of formula (d-1) or (d-2).

19. (Currently Amended) A compound according to claim 17 wherein  
n is 0; X is CH; R<sup>1</sup> is C<sub>1-6</sub>alkyl; R<sup>2</sup> is hydrogen; ~~R<sup>3</sup> is a group of formula  
(b-1) wherein -Z is a heterocyclic ring system selected from (c-1);~~ t is 2; ~~-Z is a  
heterocyclic ring system selected from (c-1);~~ R<sup>12</sup> is hydrogen; R<sup>13</sup> is hydrogen; and R<sup>5</sup>  
and R<sup>6</sup> are on adjacent positions and taken together form a bivalent radical of formula  
(d-2).


20. (Previously Presented) A compound selected from compounds No 16, compound No  
144, and compound No. 145:



compound 16



Compound 144



Compound 145

21. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 17.
22. (Currently Amended) A combination of a compound as claimed in Claim 17 with a chemotherapeutic agent selected from the group consisting of 5-fluorouracil, leucovorin, 5'-amino-5'-deoxythymidine, carbogen, oxygen, Flucosol 10 DA, 2,3-DPG, BW12C, cisplatin, bleomycin, pentoxifyline, hydrolazine, LBSO, calcium channel blockers, methylating agents, and topoisomerase 1 inhibitors.